Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Oliver Löwrick has worked on the following 10 EPO patent applications which have been published in the last five years:

EP11725479

AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES

IPC classification:
A61K 31/425, C07D 513/04
Applicant:
Sanofi, S.A.
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Status:
EXAMINATION IN PROGRESS
EP12799541

INSULIN GLARGINE VERSUS METFORMIN FOR THE FIRST-LINE TREATMENT OF EARLY TYPE 2 DIABETES

IPC classification:
A61K 38/28, A61P 3/10
Applicant:
Sanofi, S.A.
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION WITHDRAWN
EP13713425

BASAL INSULIN THERAPY

IPC classification:
A61K 38/28, A61P 3/10, A61P 9/10
Applicant:
Sanofi, S.A.
Applicant:
Sanofi-Aventis Deutschland GmbH
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
GRANT OF PATENT INTENDED
EP11701123

OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

IPC classification:
A61K 31/415, A61P 9/00, A61P 11/00, A61P 13/12, A61P 25/28, A61P 29/00, A61P 37/00, C07D 231/20, C07D 231/22, C07D 401/04, C07D 401/12, C07D 403/12, C07D 405/12, C07D 413/12, C07D 417/12
Applicant:
Sanofi, S.A.
Applicant:
Sanofi
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14305886

A novel soluble biomarker for insulin resistance

IPC classification:
G01N 33/68
Applicant:
Universität Leipzig KöR
Applicant:
Sanofi, S.A.
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP12701015

PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9

IPC classification:
A61K 39/395, A61P 3/06, C07K 16/40
Applicant:
Sanofi, S.A.
Agent:
Jörk Zwicker, Zwicker Schnappauf & Partner Patentanwälte PartG mbB (ZSP)
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
EXAMINATION IN PROGRESS
EP14714692

TREATMENT OF DIABETES MELLITUS BY LONG ACTING FORMULATIONS OF INSULINS

IPC classification:
A61K 9/00, A61K 38/28, A61P 3/10
Applicant:
Sanofi, S.A.
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
EXAMINATION IN PROGRESS
EP11726768

HETEROCYCLIC SUBSTITUTED METHOXYPHENYL DERIVATIVES WITH OXOGROUP, METHOD FOR PRODUCING SAME AND USE AS GPR40 RECEPTOR MODULATORS

IPC classification:
A61K 31/404, A61K 31/428, A61K 31/4704, A61K 31/538, A61K 31/5383, C07D 209/34, C07D 215/227, C07D 265/36, C07D 277/68, C07D 498/04
Applicant:
Sanofi, S.A.
Applicant:
Sanofi
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13155801

USE OF INSULIN GLARGINE TO REDUCE OR PREVENT CARDIOVASCULAR MORBIDITY AND MORTALITY IN PRE-DIABETES PATIENTS

IPC classification:
A61K 38/28, A61P 3/08, A61P 3/10, A61P 9/10
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
PATENT GRANTED
EP15719657

NEW ADMINISTRATION ROUTES OF INSULIN, INSULIN ANALOGS OR DERIVATIVES OF INSULIN

IPC classification:
A61K 38/28, A61P 7/12
Applicant:
Sanofi, S.A.
Agent:
Herzog Fiesser & Partner Patentanwälte PartG mbB
Agent:
Oliver Löwrick, Sanofi-Aventis Deutschland GmbH
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature